Google
BBIO Stock Analysis — BRIDGEBIO PHARMA INC (Healthcare >> Biotechnology)
BBIO FAQ
What is BBIO's ROE?
BRIDGEBIO PHARMA INC reports a Return on Equity (ROE) of 32.00%.
What is BBIO's dividend yield?
BRIDGEBIO PHARMA INC offers a dividend yield of 0.00%.
What is BBIO's Quality Score?
Our AI rates BBIO's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BBIO?
Our AI Timing Score for BBIO is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BBIO belong to?
BRIDGEBIO PHARMA INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
BBIO AI Analysis Summary
Our AI summary for BBIO: BRIDGEBIO PHARMA INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 32.00%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 80.09
Price
-2.05
(-2.50%)
Day Change
|
|
|---|
BBIO, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 80.09 |
| PBV / Sector |
-7.09 / 5.20
|
| Earning Per Share | -3.61 |
| PE / Sector |
N/A / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
275.92 M
GREAT
|
| Average 1W Daily Value |
189.41 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
64% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:31 |
| Symbol | BBIO |
| Name | BRIDGEBIO PHARMA INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 195.86 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 16,088.04 / 9,903.94 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3160 Porter Drive, Palo Alto, CA, United States, 94304
Phone: 650 391 9740
Website: https://bridgebio.com
Employees: 834
Sector: Healthcare >> Biotechnology
Description: BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap